Breaks Categories: News

MondayJan 08, 2018 12:28 pm

CannabisNewsBreaks – NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9) Enters Research and Development MOU with Scientus Pharma Inc.

NeutriSci International (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9) this morning announced that it has entered into a major research and development (R&D) Memorandum of Understanding (“MOU”) with Scientus Pharma Inc. In accordance of the terms set forth in the MOU, the two companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for current retail distribution networks throughout Canada. "This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant…

Continue Reading

FridayJan 05, 2018 10:19 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names New Chief Marketing Officer

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Sung Kang as its new chief marketing officer, effective January 8, 2018. Kang brings more than 17 years of marketing experience to the ABcann team, having previously served as the head of marketing for the Mike’s Beverage Company, Canada’s leading ready-to-drink and cider business. “Sung is a great addition to the leadership team,” Barry Fishman, CEO of ABcann, stated in the news release. “We believe his marketing expertise combined with his experience in the alcohol and consumer health industries will prove invaluable to ABcann’s future growth. He…

Continue Reading

ThursdayJan 04, 2018 11:35 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Trading on OTCQX Best Market

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, this morning announced that Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has qualified to trade on the OTCQX® Best Market. Subsequently, Lexaria has upgraded from the OTCQB® Venture Market, beginning today. “Lexaria has made notable progress over the past twelve months in all aspects of its business, and will receive even more recognition by upgrading to OTCQX,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “Lexaria…

Continue Reading

TuesdayJan 02, 2018 10:32 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Receives Cannabis Oil Production License from Health Canada

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has been licensed by Health Canada to produce medical cannabis oils. Per the update, Health Canada will conduct a final inspection when ABcann has saleable extracted finished products. ABcann expects to complete this process in the first quarter of 2018. “Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed,” Barry Fishman, CEO of ABcann, stated in the news release. “The expansion and innovation of our product lines…

Continue Reading

TuesdayJan 02, 2018 9:44 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Adds Dr. Brian O’Connor to Advisory Board

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced the addition of Dr. Brian O’Connor, a consultant in respiratory medicine, to its advisory board. Per the update, O’Connor is a clinical expert in the areas of asthma, chronic obstructive pulmonary disease (“COPD”), allergic disease and lung cancer. He is also an active clinical researcher committed to investigating new treatment strategies in airways disease. “Dr. O’Connor brings a great reputation of clinical excellence and scholarly research,” Dr. Lui Franciosi, CEO of Veritas, stated in the news release. “He will advise us on…

Continue Reading

FridayDec 29, 2017 9:44 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Visits Clinical Trial Facility in San Juan, Puerto Rico

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico. Per the release, this will be the site where the company’s research arm, Cannevert Therapeutics Ltd. (“CTL”), will be conducting its first human study of CTL-X, a cannabis strain targeting the pain management market. Speaking about the FDI clinical trial facility in this morning's update, Veritas CEO Lui Franciosi stated, “I was very impressed by their Phase I and Phase II-III clinical trial…

Continue Reading

ThursdayDec 28, 2017 10:16 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Subsidiary Receives Dealer License from Health Canada

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that Health Canada has issued its research and development subsidiary, Cannevert Therapeutics Ltd. (“CTL”), a dealer license allowing it to possess, analyze, sale, send, transport and deliver cannabis, hemp and related products. Per the release, reception of this license marks a “significant step” for CTL as it seeks to discover and develop new therapeutic cannabis strains while also providing commercial chemical and biological testing services for licensed producers under Health Canada guidelines. “We are excited that Cannevert scientists will now not only…

Continue Reading

ThursdayDec 21, 2017 9:55 am

CannabisNewsBreaks – DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Enters LOI for Merger with Tokyo Smoke; Announces Investment from Aphria Inc.

Premium cannabis lifestyle brand DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) this morning announced its entry into a binding letter of intent setting out the terms pursuant to which it proposes to acquire all of the issued and outstanding shares of Tokyo Smoke. Per the update, the proposed merger will create a uniquely positioned cannabis company combining a best-in-class craft cannabis producer and a retail-focused cannabis company. The combined company is expected to operate under the name “Hiku Brands Company Ltd.” in reference to the brand house containing premium cannabis brands DOJA, Tokyo Smoke and Van der Pop. Additionally,…

Continue Reading

MondayDec 18, 2017 12:08 pm

CannabisNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Added to Horizons Marijuana Life Sciences Index ETF

Horizons ETFs Management (Canada) Inc. recently announced completion of its quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF (“HMMJ”). Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is one of 11 new holdings that have been added to HMMJ’s portfolio, which is the world’s first ETF offering direct exposure to North American-listed securities involved with marijuana bioengineering and production. “Cannabis has been one of the newest and fastest-growing asset classes of 2017, presently valued at approximately $23 billion,” Steve Hawkins, president and CEO of Horizons ETFs, stated in a news release.…

Continue Reading

FridayDec 15, 2017 9:24 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Launches New Research Programs

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning said it is engaging in a new topical skin cream research and development ("R&D") program; R&D regarding nicotine edibles; and provided an update on existing R&D programs. The company has developed topical cream products for the delivery of cannabinoids as an addition to its DehydraTECH™ technology. Laboratory testing for human skin absorption and penetration characteristics are scheduled for early 2018 for various formulations. Following its recent nicotine patent grant, Lexaria is advancing its research focus on edible forms of nicotine that could utilize the company’s DehydraTECH™ technology. Additionally, Lexaria plans to further…

Continue Reading